Harrow Health, Inc.

Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Harrow Health, Inc. (NASDAQ: HROW; HROWL; HROWM) resulting from allegations that Harrow may have issued materially misleading business information to the investing public.

If you purchased Harrow securities and would like to join the prospective action, please click “Join This Class Action.”

If you purchased Harrow securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

Details of the case:

On February 22, 2023, market analyst Bonitas Research published a report on Harrow. The report alleged, among other things, that Harrow had concealed a U.S. Department of Justice (“DOJ”) investigation into its sales practices, that it had engaged in suspect transactions with former subsidiaries in order to enrich Company insiders at the expense of shareholders, and that it engaged in a pattern of sub-par business practices, resulting in a slew of warnings from the U.S. Food and Drug Administration (“FDA”).

On this news, Harrow’s stock price fell 10% during intraday trading from the prior closing price.

Follow us on:

Why Rosen Law

The Rosen Law Firm has been ranked among the top 4 law firms each year since 2013 for the number of successful securities class actions on behalf of investors. In 2019 alone, our firm recovered $438 million for investors.

Investors should carefully identify and select experienced counsel with a track record of success leading securities class actions. Often other firms issue press releases about class actions yet do not have comparable experience or resources.

Institutional Shareholders Services ranked the Rosen Law Firm # 1 for the number of securities class action recoveries in 2017.

The Rosen Law Firm represents investors throughout the globe. Our mission is to prosecute securities fraud class actions and protect shareholders’ rights.

Scroll to Top